Compare
Cadrenal Therapeutics, Inc. vs Lexaria Bioscience Corp. vs Pulmatrix, Inc. vs International Stem Cell Corp
| Latest fiscal year | Cadrenal Therapeutics, Inc. CVKD | Lexaria Bioscience Corp. LEXX | Pulmatrix, Inc. PULM | International Stem Cell Corp ISCO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $705.9K | n/a | $9.10M |
| Revenue growth (YoY) | n/a | +52.0% | n/a | +0.2% |
| Gross margin | n/a | 99.6% | n/a | 55.7% (computed) |
| Operating margin | n/a | n/m | n/a | -2.9% |
| Net margin | n/a | n/m | n/a | -4.6% |
| Net income | -$13.24M | -$11.90M | -$5.16M | -$418.0K |
| EPS (Diluted) | -$6.64 | -$0.66 | -$1.41 | -$0.05 |
| Operating cash flow | -$12.60M | -$10.45M | -$5.43M | $8.0K |
| Free cash flow | -$12.61M | -$10.48M | n/a | -$35.0K |
| Cash & equivalents | $4.01M | n/a | $4.09M | n/a |
| Total assets | $4.33M | $4.18M | $4.14M | $4.82M |
| Total liabilities | $1.59M | $1.57M | $329.0K | $4.58M |
| Shareholders' equity | $2.74M | $2.99M | $3.81M | -$4.06M |
| Return on year-end equity | -483.3% | -398.1% | -135.5% | n/a |
| Shares outstanding | 2.34M | 19.56M | 3.65M | 8.00M |
Revenue, most recent five fiscal years
| Fiscal year | Cadrenal Therapeutics, Inc. | Lexaria Bioscience Corp. | Pulmatrix, Inc. | International Stem Cell Corp |
|---|---|---|---|---|
| Latest | n/a | $705.9K Ended 2025-08-31 | $7.81M Ended 2024-12-31 | $9.10M Ended 2025-12-31 |
| 1 year earlier | n/a | $464.3K Ended 2024-08-31 | $7.30M Ended 2023-12-31 | $9.09M Ended 2024-12-31 |
| 2 years earlier | n/a | $226.2K Ended 2023-08-31 | $6.07M Ended 2022-12-31 | $7.79M Ended 2023-12-31 |
| 3 years earlier | n/a | $255.4K Ended 2022-08-31 | $5.17M Ended 2021-12-31 | $8.18M Ended 2022-12-31 |
| 4 years earlier | n/a | $722.7K Ended 2021-08-31 | $12.63M Ended 2020-12-31 | $7.18M Ended 2021-12-31 |